Trial Information
Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment48% Female51%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-BIP-301Data PartnerJohnson & JohnsonCondition StudiedBipolar DisorderMean/Median Age (Years)41
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
Approved Data Requests Associated with this Trial
- 2024-0244 : Reevaluating Treatment Response Prediction in Mental Health: A Study on Generalizability
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials